Lienau F S, Füllgraf H, Moser A, Feuerstein T J
Neurochemical Research Group, Department of Neurology, University of Lübeck, Lübeck, Germany.
Eur J Neurol. 2007 Oct;14(10):1162-9. doi: 10.1111/j.1468-1331.2007.01903.x.
The effectiveness of cannabinoids (CB) in the treatment of pain in patients with multiple sclerosis (MS) varies. The pathogenesis of pain in MS is diverse as are the possible effects of CB at different sites of CB receptors in the peripheral and central nervous system, this may explain the variable impact on individual patients. The aim of this review is to summarize pre-clinical and clinical studies to explain this variability from a neuropharmacological point of view. Future studies are needed to examine specific effects on distinct symptoms in homogenous groups of patients.
大麻素（CB）治疗多发性硬化症（MS）患者疼痛的效果各不相同。MS疼痛的发病机制多种多样，CB在外周和中枢神经系统不同CB受体位点的可能作用也各不相同，这可能解释了对个体患者的影响存在差异的原因。本综述的目的是总结临床前和临床研究，从神经药理学角度解释这种变异性。未来需要开展研究，以考察对同质患者群体中不同症状的特定影响。
